Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

56 trials found

Recruiting 50,000 target

RIVER At Home Ketamine Protocols

RIVER Foundation

NCT06070766

Recruiting Phase 3 1,700 target

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera

NCT07284901

Recruiting Phase 3 1,200 target

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera

NCT07284979

Recruiting Phase 3 1,000 target

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Bristol-Myers Squibb

NCT06561386

Recruiting 1,000 target

Abbott Cephea Mitral Valve Disease Registry

Abbott Medical Devices

NCT07069673

Recruiting Phase 3 686 target

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Daiichi Sankyo

NCT06899126

Recruiting Phase 3 674 target

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Celcuity

NCT06757634

Recruiting Phase 3 662 target

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Loxo Oncology

NCT05254743

Recruiting Phase 1 616 target

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Revolution Medicines

NCT06162221

Recruiting Phase 3 600 target

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Eli Lilly and Company

NCT06972472

Recruiting Phase 3 600 target

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Merck Sharp & Dohme

NCT06345729

Recruiting Phase 3 590 target

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Biotest

NCT05722938

Recruiting Phase 3 582 target

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Daiichi Sankyo

NCT06819007

Recruiting Phase 3 520 target

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GlaxoSmithKline

NCT06679101

Recruiting NA 500 target

Improving Psychological and Vestibular Health: MINDGAPS

University of Montana

NCT05986279

Recruiting 500 target

Ketamine Treatment Plans for Chronic Conditions

RIVER Foundation

NCT06038409

Recruiting Phase 3 466 target

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Incyte Corporation

NCT07214779

Recruiting Phase 3 460 target

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

AbbVie

NCT06614192

Recruiting Phase 3 420 target

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Revolution Medicines

NCT06881784

Recruiting Phase 2 410 target

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences

NCT06295731

Recruiting NA 400 target

Trauma and Cardiometabolic Health in an American Indian Community

Montana State University

NCT06878885

Recruiting Phase 2 375 target

LMN-201 for Prevention of C. Difficile Infection Recurrence

Lumen Bioscience

NCT05330182

Recruiting Phase 2 372 target

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Merck Sharp & Dohme

NCT06797635

Recruiting Phase 2 300 target

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Olatec Therapeutics

NCT05658575

Recruiting Phase 3 300 target

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NewAmsterdam Pharma

NCT07219602

Recruiting Phase 3 292 target

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

GlaxoSmithKline

NCT05757102

Recruiting Phase 2 290 target

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Merck Sharp & Dohme

NCT05139017

Recruiting Phase 2 240 target

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Hoffmann-La Roche

NCT07112872

Recruiting 200 target

Impella RP Flex with Smart Assist

Abiomed

NCT06637644

Recruiting 200 target

Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00339287

Recruiting NA 150 target

TTVR Early Feasibility Study

Medtronic Cardiovascular

NCT04433065

Recruiting Phase 2 134 target

Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors

University of Colorado, Denver

NCT07001241

Recruiting NA 130 target

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

Acoustic Wave Cell Therapy

NCT06862648

Recruiting 120 target

Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06120244

Recruiting NA 120 target

Gut Microbiota-dependent Health Impacts of Haskap Berries

Montana State University

NCT06546020

Recruiting NA 120 target

Contoura With Phorcides Compared to Wavefront Optimized LASIK

Daniel Terveen

NCT05486546

Recruiting Phase 1 117 target

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Georgiamune

NCT06425926

Recruiting Phase 2 105 target

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Blueprint Medicines Corporation

NCT06931405

Recruiting NA 100 target

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Healeon Medical

NCT04238143

Recruiting Phase 2 87 target

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Vyriad

NCT04291105

Recruiting NA 80 target

External Therapy for Tinnitus Management

Restorear Devices

NCT07017998

Recruiting NA 75 target

Understanding the Role of Doulas in Supporting People With PMADs

University of Montana

NCT05763537

Recruiting Phase 2 73 target

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

BicycleTx Limited

NCT06933329

Recruiting Early Phase 1 60 target

Group Telehealth Behavioral Cough Suppression Therapy

University of Montana

NCT06706765

Recruiting Phase 2 50 target

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Hoffmann-La Roche

NCT06450639

Recruiting NA 50 target

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

InspireMD

NCT06653387

Recruiting NA 50 target

Rural Autistic Individuals - Supporting Expression

Montana State University

NCT07054866

Recruiting 48 target

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

University of Washington

NCT04489719

Recruiting NA 43 target

The Food for Health Study

University of Montana

NCT07254689

Recruiting Phase 2 40 target

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Incyte Corporation

NCT07213973

Recruiting NA 36 target

Making INformed Decisions in Gaze and Postural Stability: A Pilot Feasibility Study

University of Montana

NCT05391932

Recruiting NA 36 target

Preliminary Testing of Cafe Move for Primary Prevention of Physical Frailty

University of Montana

NCT05720507

Recruiting NA 30 target

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

Montana State University

NCT07344727

Recruiting Phase 3 29 target

Creatine for Depressed Male and Female Methamphetamine Users

Montana State University

NCT02568878

Recruiting NA 24 target

PT for Montana Children With NMD Using Hippotherapy and the Equine Environment

University of Montana

NCT06887647

Recruiting Phase 4 20 target

The PRIME Study: A Randomized, Controlled, Prospective Study

Vance Thompson Vision - MT

NCT04549935

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →